Specialty Pharmacy Is No Longer Optional Infrastructure
The organizations that move now — with the right foundation and the right partners — will enter the next planning cycle with a specialty pharmacy that functions as a true strategic asset.
The organizations that move now — with the right foundation and the right partners — will enter the next planning cycle with a specialty pharmacy that functions as a true strategic asset.
Polypharmacy is a cost and safety problem that is solvable. The right technology platform can reduce it by identifying risky regimens, route specific “stop/switch/consolidate” opportunities to clinicians, and track whether changes stick through refill and adherence patterns.
Every day, patients are making agonizing choices to skip medications due to cost, and the fallout is evident in worsening health and avoidable hospitalizations. Health systems are in a prime position to break this cycle by acting as advocates for their patients’ financial as well as physical well-being.
There are a number of important ways AI will impact patients, providers and pharmacies in the coming year. They break down into three key areas.
Through collaboration between regulators and healthcare stakeholders, telehealth prescribing can continue to expand treatment access while maintaining proven safety standards.
The best “gift” for a person with chronic conditions is the emotional support and education needed to stay adherent to medications during the hectic holiday season.
Top challenges impacting specialty pharmacy outcomes, and how health systems may achieve efficiencies and enhance performance for optimal outcomes.
Losing these retail medication outlets creates more than just pharmacy deserts. In many low-income and underserved areas, drugstores also serve as grocery stores and hubs for essential services, and hence their closures mean communities lose crucial access points for a variety of goods and services.
if we can shift the way we deliver information, we can change the entire culture of pharmacy in a way that relieves some of the burden on the pharmacists and improves patient outcomes at the same time.
A customer of Cost Plus Drugs received an email from the company in October stating that “due to skyrocketing demand,” shipping times have been delayed. Marley Drug, a competitor, said its company has not experienced delays and presented itself as an alternative for Americans.
It is Mark Cuban Cost Plus Drug Company's first collaboration with a health plan. The pharmacy company will not be replacing Capital Blue Cross' existing pharmacy benefits manger, but instead will be an additional option for members to choose.
The company, created by the founder of Zocdoc, is focused on providing low-cost and sometimes no-cost care. Currently, it only offers prescriptions for Covid-19 antivirals.
The startup provides pharmacy delivery apps and services for health systems and telehealth companies, enabling prescriptions to be delivered to patients in two hours or less.
Thirty Madison, which operates three brands for hair loss, migraines and acid reflux, raised $47 million in a series B round. Polaris Partners led the round, and Johnson & Johnson participated as an investor.
Walmart acquired CareZone’s medication management technology and intellectual property. The purchase is the latest move by Walmart to compete with its pharmacy services.